Pancreatic ductal adenocarcinoma is probably the most lethalcancer, with a median survival of less than 6 months and a 5-yearsurvival rate of less than 5%. The cause of pancreatic ductaladenocarcinoma is unknown, and this type of cancer resists allcurrently available treatments. Increasing evidence indicatesthat inflammation around tumors, including infiltration by mastcells, facilitates cancer growth, especially that of pancreaticductal adenocarcinoma.1
Mast cells are derived from a unique bone marrow precursor,and they mature in the tissues. They are commonly known fortheir role in allergic and anaphylactic reactions, during whichthey secrete numerous vasoactive, . . . [Full Text of this Article]
Source Information
From the Tufts University School of Medicine and Tufts Medical Center — both in Boston.
This article has been cited by other articles:
Zhang, Z., Huang, Y., Newman, K., Gu, J., Zhang, X., Wu, H., Zhao, M., Xianyu, Z., Liu, X.
(2009). Reexpression of Human Somatostatin Receptor Gene 2 Gene Mediated by Oncolytic Adenovirus Increases Antitumor Activity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand against Pancreatic Cancer. Clin. Cancer Res.
15: 5154-5160
[Abstract][Full Text]
Fiedler, G. M., Leichtle, A. B., Kase, J., Baumann, S., Ceglarek, U., Felix, K., Conrad, T., Witzigmann, H., Weimann, A., Schutte, C., Hauss, J., Buchler, M., Thiery, J.
(2009). Serum Peptidome Profiling Revealed Platelet Factor 4 as a Potential Discriminating Peptide Associated with Pancreatic Cancer. Clin. Cancer Res.
15: 3812-3819
[Abstract][Full Text]
Previous
